75 percent Saudis will be obese by 2020: Study

Updated 02 May 2015
0

75 percent Saudis will be obese by 2020: Study

Seventy-five percent of Saudi population will be obese by 2020 if no preventive steps are taken, a study has warned.
The research, conducted by Nasser Al-Salem Al-Qahtani, as a Ph.D. thesis at an Australian university, has focused on causes of obesity among intermediate and secondary school students in Riyadh.
According to the findings, obesity has increased by 50.6 percent among teenagers in both rural and urban areas, with urban areas accounting for 59.4 percent and rural 36.9 percent.
The researcher cited a number of factors linked to obesity and over-weight, including the presence of a driver with family, daily consumption of soft drinks, watching TV and using computers and other electronic devices.
The study shows that obesity among children is growing at an alarming rate in the Kingdom, with the figure reaching over 50 percent in 2010 as against 11 percent in 1988.
Nagwa Mousa, a medical expert, warned against the rise in obesity among new generations. Intensive awareness campaigns on risks and side-effects of obesity need to be launched, she said.
She strongly advised that strict control should be observed on the type of food and that daily physical exercises be encouraged among women and children in order to fight obesity.
Obesity problem is plaguing the world, especially developed countries, and experts have advised against limited use of junk food such as burgers and wafers, besides aeriated drinks. Lifestyle is one of the main reasons for obesity.


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”